Systemic effects of ionizing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: the influence of inflammation and radiation toxicity

International Journal of Radiation Biology

Volumn 93, Issue 7, 2017, Pages 683-696

  Jelonek, Karol ^a   Pietrowska, Monika ^a   Widlak, Piotr ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Ionizing radiation; lipidomics; metabolomics; normal tissue toxicity; plasma; proteomics; serum

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

BLOOD ANALYSIS; CANCER PATIENT; CANCER RADIOTHERAPY; HUMAN; INFLAMMATION; IONIZING RADIATION; METABOLOME; METABOLOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RADIATION HAZARD; RADIOSENSITIVITY; REVIEW; TREATMENT RESPONSE; ADULT; AGED; BLOOD; FEMALE; MALE; MIDDLE AGED; NEOPLASMS; RADIATION INJURIES; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; YOUNG ADULT;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLOME; MIDDLE AGED; NEOPLASMS; PROTEOME; RADIATION INJURIES; RADIATION, IONIZING; RADIOTHERAPY DOSAGE; YOUNG ADULT;

EID: 85021689237     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553002.2017.1304590     Document Type: Review

References (96)

1. Alsbeih G, Story MD, Maor MH, Geara FB, Brock WA., 2003. Chromosomal fragility syndrome and family history of radiosensitivity as indicators for radiotherapy dose modification. Radiother Oncol. 66:341–344.
2. Alsner J, Andreassen CN, Overgaard J., 2008. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol. 18:126–135.
3. Andreassen CN., 2010. Searching for genetic determinants of normal tissue radiosensitivity–are we on the right track? Radiother Oncol. 97:1–8.
4. Andreassen CN, Alsner J., 2009. Genetic variants and normal tissue toxicity after radiotherapy:a systematic review. Radiother Oncol. 92:299–309.
5. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13:1050–1059.
6. Balkwill F, Mantovani A., 2001. Inflammation and cancer:back to Virchow? The Lancet. 357:539–545.
7. Barcellos-Hoff MH., 1998. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res. 150:S109–S120.
8. Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, et al. 2012. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity:a prospective analysis study. Lancet Oncol. 13:65–77.
9. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet NG., 2009. Normal tissue reactions to radiotherapy:towards tailoring treatment dose by genotype. Nat Rev Cancer. 9:134–142.
10. Becciolini A, Giannardi G, Cionini L, Porciani S, Fallai C, Pirtoli L., 1984. Plasma amylase activity as a biochemical indicator of radiation injury to salivary glands. Acta Radiol Oncol. 23:9–14.
11. Bentzen SM., 2006. Preventing or reducing late side effects of radiation therapy:radiobiology meets molecular pathology. Nat Rev Cancer. 6:702–713.
12. Bentzen SM., 2008. From cellular to high-throughput predictive assays in radiation oncology:challenges and opportunities. Semin Radiat Oncol. 18:75–88.
13. Bertho JM, Demarquay C, Frick J, Joubert C, Arenales S, Jacquet N, Sorokine-Durm I, Chau Q, Lopez M, Aigueperse J, et al. 2001. Level of Flt3-ligand in plasma:a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol. 77:703–712.
14. Boguszewicz Ł, Hajduk A, Mrochem-Kwarciak J, Skorupa A, Ciszek M, Heyda A, Składowski K, Sokół M., 2016. 1H NMR based metabolomic approach to monitoring of the head and neck cancer treatment toxicity. Metabolomics. 12:1–15.
15. Brush J, Lipnick SL, Phillips T, Sitko J, McDonald JT, McBride WH., 2007. Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol. 17:121–130.
16. Cai XW, Shedden K, Ao X, Davis M, Fu XL, Lawrence TS, Lubman DM, Kong FM., 2010. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 77:867–876.
17. Cai XW, Shedden KA, Yuan SH, Davis MA, Xu LY, Xie CY, Fu XL, Lawrence TS, Lubman DM, Kong FM., 2011. Baseline plasma proteomic analysis to identify biomarkers that predict radiation-induced lung toxicity in patients receiving radiation for non-small cell lung cancer. J Thorac Oncol. 6:1073–1078.
18. Candeias SM, Testard I., 2015. The many interactions between the innate immune system and the response to radiation. Cancer Lett. 368:173–178.
19. Chai Y, Wang J, Gao Y, Wang T, Shi F, Su J, Yang Y, Zhou X, Song L, Liu Z., 2015. Identification of biomarkers for radiation-induced acute intestinal symptoms (RIAISs) in cervical cancer patients by serum protein profiling. J Radiat Res. 56:134–140.
20. Chen GY, Nuñez G., 2010. Sterile inflammation:sensing and reacting to damage. Nat Rev Immunol. 10:826–837.
21. Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC., 2003. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages:its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 9:729–737.
22. Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, Finkelstein JN, Rubin P, Okunieff P., 2002. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 12(Suppl.1):26–33.
23. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM., 2004. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 23:1599–1607.
24. Chon BH, Loeffler JS., 2002. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist. 7:136–143.
25. Christensen E, Pintilie M, Evans KR, Lenarduzzi M, Menard C, Catton CN, Diamandis EP, Bristow RG., 2009. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res. 15:5576–5583.
26. Chung LP, Bentley DR, Reid KB., 1985. Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J. 230:133–141.
27. Coussens LM, Werb Z., 2002. Inflammation and cancer. Nature. 420:860–867.
28. Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US., 2016. Modern radiotherapy concepts and the impact of radiation on immune activation. Front Oncol. 6:141.
29. Di Maggio FM, Minafra L, Forte GI, Cammarata FP, Lio D, Messa C, Gilardi MC, Bravata V., 2015. Portrait of inflammatory response to ionizing radiation treatment. J Inflamm. 12:14.
30. Donnelly EH, Nemhauser JB, Smith JM, Kazzi ZN, Farfan EB, Chang AS, Naeem SF., 2010. Acute radiation syndrome:assessment and management. South Med J. 103:541–546.
31. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C., 2006. Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319.
32. Garaj-Vrhovac V, Kopjar N., 2003. The alkaline comet assay as biomarker in assessment of DNA damage in medical personnel occupationally exposed to ionizing radiation. Mutagenesis. 18:265–271.
33. Green DR., 2000. Apoptosis and sphingomyelin hydrolysis. The flip side. J Cell Biol. 150:F5–7.
34. Grivennikov SI, Greten FR, Karin M., 2010. Immunity, inflammation, and cancer. Cell. 140:883–899.
35. Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G., 2015. Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer. Front Immunol. 6:556.
36. Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, Murthy V, Budrukkar A, Dinshaw K, Prabhash K, Chaturvedi P, D’Cruz A., 2012. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck:a randomized controlled trial. Radiother Oncol. 104:343–348.
37. Hall EJ, Giaccia AJ., 2006. Radiobiology for the radiologist. Philadelphia (PA):Lippincott Williams & Wilkins.
38. Hart JP, Broadwater G, Rabbani Z, Moeller BJ, Clough R, Huang D, Sempowski GA, Dewhirst M, Pizzo SV, Vujaskovic Z, Anscher MS., 2005. Cytokine profiling for prediction of symptomatic radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 63:1448–1454.
39. Hauer-Jensen M, Kong FM, Fink LM, Anscher MS., 1999. Circulating thrombomodulin during radiation therapy of lung cancer. Radiat Oncol Investig. 7:238–242.
40. Herold DM, Hanlon AL, Hanks GE., 1999. Diabetes mellitus:a predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys. 43:475–479.
41. Hopewell JW, Young CM., 1978. Changes in the microcirculation of normal tissues after irradiation. Int J Radiat Oncol Biol Phys. 4:53–58.
42. Hoyer KK, Dooms H, Barron L, Abbas AK., 2008. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev. 226:19–28.
43. Jelonek K, Pietrowska M, Ros M, Zagdanski A, Suchwalko A, Polanska J, Marczyk M, Rutkowski T, Skladowski K, Clench MR, Widlak P., 2014. Radiation-induced changes in serum lipidome of head and neck cancer patients. Int J Mol Sci. 15:6609–6624.
44. Johansson S, Svensson H, Denekamp J., 2000. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys. 48:745–750.
45. Karas M, Hillenkamp F., 1988. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem. 60:2299–2301.
46. Kerns SL, Kundu S, Oh JH, Singhal SK, Janelsins M, Travis LB, Deasy JO, Janssens AC, Ostrer H, Parliament M, Usmani N, Rosenstein BS., 2015. The prediction of radiotherapy toxicity using single nucleotide polymorphism-based models:a step toward prevention. Semin Radiat Oncol. 25:281–291.
47. Lin C, Donaldson SS, Meza JL, Anderson JR, Lyden ER, Brown CK, Morano K, Laurie F, Arndt CA, Enke CA, Breneman JC., 2012. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803–a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys. 82:1764–1770.
48. Lutgens LC, Deutz NE, Gueulette J, Cleutjens JP, Berger MP, Wouters BG, von Meyenfeldt MF, Lambin P., 2003. Citrulline:a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys. 57:1067–1074.
49. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ., 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 169:1485–1490.
50. Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman CN, Whiteley G, et al. 2006. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res. 66:1844–1850.
51. Neta R., 1997. Modulation with cytokines of radiation injury:suggested mechanisms of action. Environ Health Perspect. 105(Suppl.6):1463–1465.
52. Nylund R, Lemola E, Hartwig S, Lehr S, Acheva A, Jahns J, Hildebrandt G, Lindholm C., 2014. Profiling of low molecular weight proteins in plasma from locally irradiated individuals. J Radiat Res. 55:674–682.
53. Oh JH, Craft JM, Townsend R, Deasy JO, Bradley JD, El Naqa I., 2011. A bioinformatics approach for biomarker identification in radiation-induced lung inflammation from limited proteomics data. J Proteome Res. 10:1406–1415.
54. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR., 2005. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer:results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 6:757–764.
55. Paiva B, Merino J, San Miguel JF., 2016. Utility of flow cytometry studies in the management of patients with multiple myeloma. Curr Opin Oncol. 28:511–517.
56. Palmblad M, Tiss A, Cramer R., 2009. Mass spectrometry in clinical proteomics–from the present to the future. Proteomics Clin Appl. 3:6–17.
57. Pasi F, Facoetti A, Nano R., 2010. IL-8 and IL-6 bystander signalling in human glioblastoma cells exposed to gamma radiation. Anticancer Res. 30:2769–2772.
58. Pernot E, Hall J, Baatout S, Benotmane MA, Blanchardon E, Bouffler S, El Saghire H, Gomolka M, Guertler A, Harms-Ringdahl M, et al. 2012. Ionizing radiation biomarkers for potential use in epidemiological studies. Mutat Res. 751:258–286.
59. Pietrowska M, Jelonek K, Polanska J, Wojakowska A, Marczak L, Chawinska E, Chmura A, Majewski W, Miszczyk L, Widlak P., 2015. Partial-body irradiation in patients with prostate cancer treated with IMRT has little effect on the composition of serum proteome. Proteomes. 3:117.
60. Pietrowska M, Polanska J, Walaszczyk A, Wygoda A, Rutkowski T, Skladowski K, Marczak L, Stobiecki M, Marczyk M, Polanski A, Widlak P., 2011. Association between plasma proteome profiles analysed by mass spectrometry, a lymphocyte-based DNA-break repair assay and radiotherapy-induced acute mucosal reaction in head and neck cancer patients. Int J Radiat Biol. 87:711–719.
61. Pietrowska M, Widlak P., 2012. MALDI-MS-based profiling of serum proteome:detection of changes related to progression of cancer and response to anticancer treatment. Int J Proteom. 2012:10.
62. Popanda O, Marquardt JU, Chang-Claude J, Schmezer P., 2009. Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res. 667:58–69.
63. Rifai N, Gillette MA, Carr SA., 2006. Protein biomarker discovery and validation:the long and uncertain path to clinical utility. Nat Biotechnol. 24:971–983.
64. Ros-Mazurczyk M, Jelonek K, Pietrowska M, Zagdanski A, Suchwalko A, Jastrzab T, Polanska J, Chawinska E, Majewski W, Dominczyk I, et al. 2016a. Radiotherapy-induced changes in serum lipid profile of patients with prostate or head and neck cancer. Jacobs J Radiat Oncol. 3:030.
65. Ros-Mazurczyk M, Wojakowska A, Marczak L, Polanski K, Pietrowska M, Jelonek K, Dominczyk I, Hajduk A, Rutkowski T, Skladowski K, Widlak P., 2016b. Ionizing radiation affects profile of serum metabolites:increased level of 3-hydroxybutyric acid in serum of cancer patients treated with radiotherapy. Acta Biochim Pol. 63:1–5.
66. Rosenstein BS., 2011. Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics. 12:267–275.
67. Rube CE, Palm J, Erren M, Fleckenstein J, Konig J, Remberger K, Rube C., 2008. Cytokine plasma levels:reliable predictors for radiation pneumonitis? PLoS One. 3:e2898.
68. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN., 1995. A perpetual cascade of cytokines post irradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 33:99–109.
69. Rubner Y, Muth C, Strnad A, Derer A, Sieber R, Buslei R, Frey B, Fietkau R, Gaipl US., 2014. Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol. 9:89.
70. Ruhle PF, Fietkau R, Gaipl US, Frey B., 2016. Development of a modular assay for detailed immunophenotyping of peripheral human whole blood samples by multicolor flow cytometry. IJMS. 17:1316–1344.
71. Schaue D, Kachikwu EL, McBride WH., 2012. Cytokines in radiobiological responses:a review. Radiat Res. 178:505–523.
72. Schaue D, Micewicz ED, Ratikan JA, Xie MW, Cheng G, McBride WH., 2015. Radiation and inflammation. Semin Radiat Oncol. 25:4–10.
73. Schlegel R, MacGregor JT, Everson RB., 1986. Assessment of cytogenetic damage by quantitation of micronuclei in human peripheral blood erythrocytes. Cancer Res. 46:3717–3721.
74. Shacter E, Weitzman SA., 2002. Chronic inflammation and cancer. Oncology (Williston Park, NY) 16:217–226, 229.
75. Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, et al. 2013. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 339:211–214.
76. Simonet WS, Hughes TM, Nguyen HQ, Trebasky LD, Danilenko DM, Medlock ES., 1994. Long-term impaired neutrophil migration in mice overexpressing human interleukin-8. J Clin Invest. 94:1310–1319.
77. Solassol J, Jacot W, Lhermitte L, Boulle N, Maudelonde T, Mange A., 2006. Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics. 3:311–320.
78. Stone HB, Coleman CN, Anscher MS, McBride WH., 2003. Effects of radiation on normal tissue:consequences and mechanisms. Lancet Oncol. 4:529–536.
79. Sykes PJ, Day TK., 2007. Requirements for identification of low dose and non-linear mutagenic responses to ionising radiation. Dose Response. 5:308–314.
80. Taylor AM, Harnden DG, Arlett CF, Harcourt SA, Lehmann AR, Stevens S, Bridges BA., 1975. Ataxia telangiectasia:a human mutation with abnormal radiation sensitivity. Nature. 258:427–429.
81. Thadikkaran L, Siegenthaler MA, Crettaz D, Queloz PA, Schneider P, Tissot JD., 2005. Recent advances in blood-related proteomics. Proteomics. 5:3019–3034.
82. Vaudel M, Sickmann A, Martens L., 2012. Current methods for global proteome identification. Expert Rev Proteom. 9:519–532.
83. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N., 2011. Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem. 286:21588–21600.
84. Weintraub NL, Jones WK, Manka D., 2010. Understanding radiation-induced vascular disease. J Am College Cardiol. 55:1–5.
85. West CM, Barnett GC., 2011. Genetics and genomics of radiotherapy toxicity:towards prediction. Genome Med. 3:52.
86. Widlak P, Jelonek Wojakowska K, Pietrowska A, Polanska M, Marczak J, Miszczyk ŁL, Składowski K., 2015. Serum proteome signature of radiation response:upregulation of inflammation-related factors, and downregulation of apolipoproteins and coagulation factors in cancer patients subjected to radiotherapy:a pilot study. Int J Radiat Oncol Biol Phys. 92:1108–1115.
87. Widlak P, Pietrowska Polanska M, Rutkowski J, Jelonek T, Kalinowska-Herok K, Gdowicz-Klosok M, Wygoda A, Tarnawski AR, Skladowski K., 2013. Radiotherapy-related changes in serum proteome patterns of head and neck cancer patients; the effect of low and medium doses of radiation delivered to large volumes of normal tissue. J Transl Med. 11:299.
88. Widlak P, Pietrowska M, Wojtkiewicz K, Rutkowski T, Wygoda A, Marczak L, Marczyk M, Polanska J, Walaszczyk A, Dominczyk I, et al. 2011. Radiation-related changes in serum proteome profiles detected by mass spectrometry in blood of patients treated with radiotherapy due to larynx cancer. J Radiat Res. 52:575–581.
89. Wilson GD, Marples B., 2007. Flow cytometry in radiation research:past, present and future. Radiat Res. 168:391–403.
90. Withers HR, Taylor JM, Maciejewski B., 1988. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys. 14:751–759.
91. Wouters BG., 2008. Proteomics:methodologies and applications in oncology. Semin Radiat Oncol. 18:115–125.
92. Wulfkuhle JD, Liotta LA, Petricoin EF., 2003. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 3:267–275.
93. Wygoda A, Maciejewski B, Skladowski K, Hutnik M, Pilecki B, Golen M, Rutkowski T., 2009. Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiat Oncol Biol Phys. 73:384–390.
94. Yu H., 2012. Typical cell signaling response to ionizing radiation:DNA damage and extranuclear damage. Chin J Cancer Res. 24:83–89.
95. Zhang JS, Nakatsugawa S, Niwa O, Ju GZ, Liu SZ., 1994. Ionizing radiation-induced IL-1 alpha, IL-6 and GM-CSF production by human lung cancer cells. Chin Med J. 107:653–657.
96. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ., 2003. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 10:541–544.